How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

153 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Children deafness - 0 to 6 years

Children deafness - 0 to 6 years Deaf children: family support and follow-up of children aged 0 to 6 years HAS/Guidelines Department/December 2009 1 GUIDELINE December 2009 CLINICAL PRACTICE GUIDELINE Deaf children: family support and follow-up of children aged 0 to 6 years - Provision made within schools excluded - Deaf children: family support and follow-up of children aged 0 to 6 years HAS/Guidelines Department/December 2009 2 The quick reference guide and full evidence report (in French (...) ) can be downloaded from Haute Autorité de Santé Service Documentation – Information des publics 2 avenue du Stade de France – F 93218 Saint-Denis La Plaine CEDEX Phone: +33 (0)1 55 93 70 00 – Fax: +33 (0)1 55 93 74 00 This document was validated by the Board of the Haute Autorité de Santé (French National Authority for Health) in Decembre 2009. © Haute Autorité de Santé – 2009 Deaf children: family support and follow-up of children aged 0 to 6 years HAS/Guidelines Department

2010 HAS Guidelines

2. Effects of Amplification on Quality of Life Among School Age Children with Single Sided Deafness

Effects of Amplification on Quality of Life Among School Age Children with Single Sided Deafness Copyright © 2011 Cincinnati Children's Hospital Medical Center; all rights reserved Page 1 of 5 Audiology/Single Sided Deafness/Amplification/BESt 104 Best Evidence Statement (BESt) Date published/posted 6/20/11 Topic: Effects of Amplification on Quality of Life Among School Age Children with Single Sided Deafness Clinical Question P: Among school age children with single sided deafness I: does (...) important indicators of QoL in the pediatric population with SSD include hearing in noise, localization, ease of listening and communicating, communication intent and behavior, nature of interpersonal relationships and involvement in recreational activities. Target Population School age children (ages 7-18 years) with single sided deafness. Children with additional learning disabilities are excluded. Recommendation It is recommended that for children with single sided deafness (SSD) amplification

2011 Cincinnati Children's Hospital Medical Center

3. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy

includes questions about prior falls (one or more v none), hearing problems (deaf to excellent), limitations in walking one block (limited a lot, limited a little, not limited), interference of social activities by physical health and/or emotional problems (all of the time to none of the time), and ability to take own medications (independently to completely unable) as well as about age, gender, height and weight, cancer type (GI v genitourinary v other), dosage (standard v dose reduced), number

2018 American Society of Clinical Oncology Guidelines

5. Hearing loss in adults: assessment and management

option options for managing single-sided deafness if needed referral for implantable devices such as cochlear implants, bone-anchored hearing aids, middle-ear implants or auditory brain stem implants, if these might be suitable (see NICE's technology appraisal guidance on cochlear implants for children and adults with severe to profound deafness and interventional procedures guidance on auditory brain stem implants) referral for medical or surgical treatments, if these might be suitable agree

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

12. Syphilis Infection in Pregnant Women: Screening

% for prematurity or low birth weight. Although infants born with congenital syphilis are often asymptomatic at birth, some may develop signs within the first several weeks of life, including rash, hemorrhagic rhinitis, lymphadenopathy, hepatosplenomegaly, and skeletal abnormalities. Additional sequelae include anemia, neurologic impairment such as blindness or deafness, and meningitis. Scope of Review To reaffirm its 2009 recommendation on screening for syphilis in pregnant women, the USPSTF commissioned

2018 U.S. Preventive Services Task Force

13. Developmental follow-up of children and young people born preterm.

(for example, autism spectrum disorder) Epilepsy that is currently being treated The presence of a hearing impairment, defined as profound deafness or impairment severe enough to need hearing aids or cochlear implant Results of national orthoptic vision screening. Record routine educational measures at Key Stage 2 (including special educational needs and disability [SEND]) on an operational delivery network-wide basis, to allow educational outcomes at 11 years to be linked to neonatal information

2017 National Guideline Clearinghouse (partial archive)

15. Hematuria : Child

cells in the urine, should also be investigated [3-5]. An assessment of the child’s height and weight should be followed by a thorough physical examination. Fevers, arthritis, rashes, soft-tissue edema, nephromegaly, abdominal masses, genital or anal bleeding suggesting sexual abuse, deafness, and costovertebral angle tenderness should be discerned. The next step is a thorough evaluation of the urine. Tea-colored urine and hematuria accompanied by proteinuria (>2+ by dip stick), red blood cell casts

2018 American College of Radiology

17. Neurodevelopmental Outcomes in Children With Congenital Heart Disease: Evaluation and Management

; CHARGE, Coloboma of the eye, Central nervous system anomalies, Heart defects, Atresia of the choanae, Retardation of growth and/or development, Genital and/or urinary defects, Ear anomalies and/or deafness; IAA, interrupted aortic arch; TA, truncus arteriosus; PDA, patent ductus arteriosus; VSD, ventricular septal defect; ASD, atrial septal defect; AVSD, atrioventricular septal defect; ADHD, attention deficit hyperactivity disorder; HLHS, hypoplastic left heart syndrome; PVS, pulmonary valve stenosis

2012 American Heart Association

18. Cardiovascular Function and Treatment in ß-Thalassemia Major

properties ( ). Table 2. Main Features of the Iron Chelators Drug FDA Approved EU Approved Route Typical Chronic Dosing, mg·kg −1 ·d −1 Frequency Excretion Main Adverse Effects Deferoxamine Yes Yes SC (IV in heart failure) 20–50 8- to 14-h infusion for5–7 d/wk 60% Urine;40% feces Sensorineural deafness, visual disturbance, skeletal abnormality, growth retardation Deferiprone Yes Yes Oral 75–100 ×3/d 75%–90% Urine Agranulocytosis, GI disturbance, arthropathy Deferasirox Yes Yes Oral 20–40 ×1/d ≈90% Feces

2013 American Heart Association

19. Transitions of Care in Heart Failure Full Text available with Trip Pro

al, 53 2005 6 mo rehosp in TC program vs UC Q-exp 121 (IG, 44; UC, 77) Age =50 y HF hosp and LVEF 1 ED visit, IG had a 32% rate and UC had 50% Hosp RNs provided IG int and UC; possible contamination across groups Jack et al, 42 2009 Project RED 30-d combination of ED visits or rehosp in Project RED vs UC PCP FU between IG and UC RCT 749 (IG, 373; UC, 376) Hosp medical and surgical patients Admitted from SNF Transferred to another service Planned hosp Blind, deaf, or suicide precautions Up to 4 d

2015 American Heart Association


Guidelines – filter by country